Overview

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy, safety, and tolerability of single doses of trospium inhalation powder (TrIP) administered to subjects with chronic obstructive pulmonary disease (COPD).
Phase:
Phase 2
Details
Lead Sponsor:
Alkermes, Inc.
Treatments:
Formoterol Fumarate
Triptorelin Pamoate
Trospium chloride